image description

Category: News

Lupus Therapeutics to Test Potential Treatment for Lupus in Takeda Collaboration

New York, NY– March 1.  The Lupus Research Alliance and clinical affiliate, Lupus Therapeutics will partner with Takeda Pharmaceutical Company Limited to evaluate the investigational biologic TAK-079 as a potential new therapy for lupus in a Phase 1 trial (NCT03724916).  TAK-079 is a fully human monoclonal antibody, meaning that it is produced in the laboratory using human […] Read More

Lupus Research Alliance Congratulates NIH on 5-Year AMP Success

February 28, 2019 NEW YORK, NY. As a co-sponsor of the National Institutes of Health (NIH) public-private Accelerating Medicines Partnership (AMP), the Lupus Research Alliance is proud to share the project’s five-year achievements reported in Nature Reviews Drug Discovery.  In the article, NIH Director Dr. Francis Collins points to new technology standards AMP created for […] Read More

Positive Early Results for BIIB059 as New Treatment Strategy

February 28, 2019 Proteins of the immune system, known as type I interferons, are responsible in part for manifestations of lupus. For this reason, type I interferons are a very attractive target for lupus drug development. In 2015, excitement surrounded the release of positive phase II data with anifrolumab, a therapeutic antibody that blocks type […] Read More

LRA-funded Research Backs New Lupus Nephritis Clinical Trial

February 28, 2019 The biotechnology company Equillium Inc. just announced plans for a Phase 1 study to test the investigational monoclonal antibody EQ001 as a potential treatment for lupus nephritis (LN) that has not responded to existing treatment. The basis for this study is in part due to work conducted by Dr. Chandra Mohan that […] Read More

Stelara® and Olumiant® Considered Promising by Lupus Expert

February 19, 2019 In Healio Rheumatology, Dr. Gregg Silverman, professor of medicine and pathology at NYU School of Medicine, provided an overview of potential lupus therapies in development.  He highlighted ustekinumab (brand name Stelara®) and baricitinib (brand name Olumiant®) as two drugs that look particularly promising. “The phase 2 extra-renal trial of baricitinib looks good; […] Read More

New Approach to Treating Lupus Nephritis

February 6, 2019 Scientists partly funded by the Lupus Research Alliance have found a potential new way to protect the kidneys in patients with lupus. A study led by Dr. Vicki Rubin Kelley of Brigham and Women’s Hospital in Boston, Massachusetts, suggests that blocking a molecule made by some cells in the kidney could reduce […] Read More

Protein Osteopontin Indicator of Lupus Nephritis, Shows Clinical Trial

February 1, 2019 Raised levels of a protein osteopontin were shown to indicate lupus nephritis and higher disease activity, in a new study conducted at 33 centers by top lupus researchers worldwide. Published in The Journal of Rheumatology, the study looked at results from 344 lupus patients. At the beginning of the study (baseline), patients […] Read More

Lupus Therapeutics Launches Peer Training Program to Help Patients Benefit from Clinical Trials

NEW YORK, NY. February 1, 2019. Lupus Research Alliance clinical affiliate Lupus Therapeutics launched the Patient Advocates for Lupus Studies (PALS) program with a pilot study to determine its effectiveness in increasing awareness of and participation in lupus clinical trials, particularly among diverse populations.  PALS was formed to address the pressing issue of underrepresentation in clinical studies […] Read More

Overcoming Challenges to Lupus Management

January 24, 2019 A recent review article in Lupus Science & Medicine provides a valuable overview of the “10 most important contemporary challenges in the management of SLE” according to a multidisciplinary team of clinicians, pharmacists and researchers from several clinics and patient organizations in France.  Their top 10 challenges include several critical factors that the […] Read More

Lupus Research Alliance and Lupus Therapeutics Partner on New Phase 3 Trial Testing Potential Benefit of Ustekinumab (Stelara®) in Lupus

The Lupus Research Alliance announced that clinical research affiliate Lupus Therapeutics is partnering with the pharmaceutical company, Janssen, to help conduct a Phase 3 trial to test existing drug ustekinumab (Stelara®) as a potential treatment for people with lupus. Stelara® is not approved by the FDA as a treatment of lupus but is indicated for […] Read More

Study Shows Kidney Transplant Improves Lupus Nephritis Survival

January 21, 2019 A study just published in Annals of Internal Medicine showed that kidney transplantation reduced deaths due to lupus nephritis — kidney inflammation caused by lupus. Up to 60 percent of people with SLE are diagnosed with lupus nephritis, which can lead to significant illness and even death. According to the National Institute of Diabetes […] Read More